Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Financing Activities (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Cash from Financing Activities for 7 consecutive years, with -$131000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 100.7% year-over-year to -$131000.0, compared with a TTM value of $66.0 million through Dec 2025, up 65.59%, and an annual FY2025 reading of $66.0 million, up 65.59% over the prior year.
  • Cash from Financing Activities was -$131000.0 for Q4 2025 at aTYR PHARMA, down from $29.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $83.9 million in Q3 2021 and bottomed at -$131000.0 in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $14.4 million, with a median of $6.9 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities tumbled 103.91% in 2024, then skyrocketed 28306.67% in 2025.
  • Year by year, Cash from Financing Activities stood at $28000.0 in 2021, then surged by 3178.57% to $918000.0 in 2022, then soared by 557.3% to $6.0 million in 2023, then surged by 212.21% to $18.8 million in 2024, then plummeted by 100.7% to -$131000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for ATYR at -$131000.0 in Q4 2025, $29.6 million in Q3 2025, and $17.9 million in Q2 2025.